Depression News and Research

Latest Depression News and Research

Immersive learning program for nursing students

University of Phoenix will debut its immersive learning center featuring state-of-the-art wireless high-fidelity SIM Man 3G "patient" mannequins that cry, talk, sweat, cough and breathe; and a high-fidelity baby that reacts astonishingly similar to its live counterpart, at a private reception and grand opening on Thursday, Oct. 29, across from its Elwood Street campus in Phoenix.

30 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

Combination of psychiatric medication and depression linked to preterm delivery

The odds triple for premature child delivery pregnant women with a history of depression who used psychiatric medication, according to a new study.

30 Oct 2009

New center to provide variety of medical services for people in and around Skid Row opened

The Weingart Center Association, JWCH Institute and the County of Los Angeles announced today the opening of the Center for Community Health Downtown Los Angeles, a state-of-the-art medical facility that provides integrated care to the more than 18,000 homeless and low-income people in and around Skid Row.

30 Oct 2009

New Wake-up Light to provide pleasant wake-up experience

According to a recent survey, an overwhelming 60 percent of Americans are not satisfied with their current way of waking up. Recognizing the need for a better way to start the day, especially with the arrival of daylight saving, Philips has announced today the launch of its Wake-up Light - an innovative product that provides a more pleasant wake-up experience.

29 Oct 2009

Initiative to help families face the challenges of parental depression and early childhood developmental delays

A Pittsburgh-based maternal and child health care collaborative will undertake a unique and innovative initiative to help families face the challenges of parental depression and early childhood developmental delays.

29 Oct 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.

29 Oct 2009

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

29 Oct 2009

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute for Quality and Efficiency in Health Care (IQWiG) published in September 2009.

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

Depressed people more likely to overstate the frequency of physical symptoms

New research shows people who feel depressed tend to recall having more physical symptoms than they actually experienced. The study indicates that depression -- not neuroticism -- is the cause of such over-reporting.

29 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate, a beta-blocker medication taken by over half a million Americans for the treatment of high blood pressure, TOPROL-XL and its authorized generic, metoprolol succinate extended-release tablets are available.

28 Oct 2009

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

October 29 is World Psoriasis Day. Conceived by patients for patients, World Psoriasis Day is a truly global event focusing on the burden of living with psoriasis. There are more than 125 million people with psoriasis/psoriatic arthritis in the world. Psoriasis is a severe chronic inflammatory disease that effects all ages, genders, races and ethnicities.

28 Oct 2009

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

NCKU President, Academician Michael Ming-Chiao Lai, signed Technology Transfer Agreement in this morning with Mr. Tou-Hsiung Yang, Chairman of Vedan International (Holding) Ltd, witnessed by Vedan Biotechnology President Shih-An (Raymond) Yang and the inventor, Prof. Huey-Lang Yang of the NCKU Institute of Biotechnology.

28 Oct 2009

Helix Hearing Care Centre and RA Centre host Healthy Aging Day

Helix Hearing Care Centre, The Senior Citizens Council of Ottawa, and the RA Centre hosted a Healthy Aging Day on Monday, where a capacity crowd of golden agers gathered to find out more about healthy hearing.

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Depression News and Research

Latest Depression News and Research

Immersive learning program for nursing students

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Combination of psychiatric medication and depression linked to preterm delivery

New center to provide variety of medical services for people in and around Skid Row opened

New Wake-up Light to provide pleasant wake-up experience

Initiative to help families face the challenges of parental depression and early childhood developmental delays

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Positive top-line results from Phase IIb clinical trial of cariprazine announced

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Depressed people more likely to overstate the frequency of physical symptoms

New clinical uses for old hypertension drug leads to several patents

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

IFPA urges WHO to act on new insights on psoriasis to help millions of psoriasis patients

NCKU transfers microalgal docosahexaenoic acid production technology to Vedan Biotechnology

Helix Hearing Care Centre and RA Centre host Healthy Aging Day

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in